Back to all webinars
Challenges in relapsed/refractory CLL: Interactive case discussions
Alessandra Tedeschi, Lucrecia Yáñez and Thorsten Zenz use interactive patient case studies to illustrate the role of prior treatment experience, genetic/cytogenetic changes, comorbidities, and patient preference in guiding treatment choices in R/R CLL.
Speakers
Case 1: Patient relapsed after venetoclax–obinutuzumab
Fast-forward to:
CLL14 trial
6479eeb08600230575524ed5
Relapse and second-line treatment
647a02eae3ec7205829484ee
BCL2 inhibitor resistance
647a040f8600230575524f04
Case 2: Patient progressing on BTK inhibitor therapy
Fast-forward to:
BTK and PLCγ2 mutations
647a049d8a7d5f057441af3e
Venetoclax after BTK inhibitor therapy
647a05bfe3ec720582948547
Covalent and non-covalent BTK inhibitors
647a07c48600230575524f50
Cellular therapy in CLL
647a08478a7d5f057441af6b
Case 3: Patient intolerant to ibrutinib
Fast-forward to:
Ibrutinib-associated rash
647a0b1f8a7d5f057441af90
Ibrutinib dose reductions in CLL
647a0bca8a7d5f057441afa2
Switching BTK inhibitor
647a0c168600230575524f7b
Q&A
Fast-forward to:
Would you continue a BTK inhibitor when switching to venR during venetoclax dose ramp up?
647a0dab8600230575524fa7
Ibrutinib plus venetoclax in the R/R setting
647a0dedeab82d0573ab71cf
What are the best treatment options for double-refractory CLL?
647a0e308a7d5f057441afd7